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ABSTRACT ·Previous research has revealed a role of repeated D1 dopamine receptor 
stimulation in the development of behavioral sensitization to the D1/D2 agonist apomor-
phine. The present experiments assessed the role of repeated D1 receptor stimulation in 
neurochemical changes accompanying locomotor sensitization to apomorphine. To assess 
direct effects of D1 stimulation oil dopamine synthesis, rats were injected with the D1 
agonist SKF 38393 (8 mg/kg), followed by an injection with the 3,4-dihydroxyphenylala-
nine (DOPA) decarboxylase inhibitor, NSD-1015. DOPA accumulation, assessed in'stri-
atal, nucleus accumbens-olfactory tubercle (NAOTl, and ventral mesencephalon (\IM) 
tissue samples, was not affected by acute SKF 38393. In the second experiment, rats ~ere 
treated with 10 daily injections of vehicle, apomorphine (5 mg/kg) or the D1 agonist SKF 
38393 (8 or 16 mg/kg). Daily measures of locomotor activity demonstrated a progressiye 
increase in the apomorphine-treated rats, but not the SKF 38393-treated rats, across the 
10 days. On day 11, all rats were»injected with NSD-1015 for measurement of DOPA 
accumulation. Dopamine synthesis was enhanced in the striatum after repeated apo~or­
phine treatment. In contrast, repeated SKF 38393 treatment resulted in either a small 
decrease or no change in DOPA accumulation in the different brain regions (stria tum, 
NAOT. VMJ. In the third experiment, tissue levels of.dopamine, 3,4-dihydroxyphenyiace-
tic acid <DOPACI and l"HJSCH 23390 binding to 0 1 receptors were measured in rats 
treated with IO daily injections of vehicle, apomorphine (5 mg/kg), or SKF 38393 (16 
mg/kgi. In the striatum and NAOT, none of the repeated drug treatments had an effect on 
DO PAC or dopamine levels. In the VM, DO PAC levels were enhanced following repeated 
apomorphine, but not repeated SKF 38393, whereas dopamine levels were not affect~d by 
either drug treatment. D1 binding was not altered by the repeated drug treatments. Since 
repeated D 1 stimulation by SKF 38393 did not produce the same alterations in doparhine 
synthesis and DOPAC levels as repeated apomorphine, the neurochemical effects ac~om­
panying locomotor sensitization to apomorphine probably are not mediated by D1 r~cep-
tors. © 1993 Wiley-Liss, Inc. 
INTRODUCTION 
Drugs that act by directly or indirectly sti~ulating 
dopamine receptors often produce a progressive aug· 
mentation of the acute behavioral effects of the drugs. 
This phenomenon, termed behavioral sensitization, has 
been demonstrated following repeated administration 
of indirect dopamine agonists such as cocaine (Kalivas 
and Stewart, 1991; Zahniser et al., 1988) and amphet-
amine (Kalivas and Stewart, 1991; Robinson and 
Becket, 1986), as. well as the direct D1/D2 dopamine 
© 1993 WILEY-LISS, INC. 
receptor agonist apomorphine (Castro et al., 1985; Mat-
tingly and Gotsick, 1989; Mattingly et al., 1988a,b). It is 
currently accepted that alterations in the nigrostriatal 
and mesolimbic dopamine systems n:ay underlie the 
development of behavioral sensitizatibn (Kalivas and 
Stewart, 1991; Robinson and Becker, l986; Rowlett et 
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al., 1991; Vaughn et al., 1990; Zahniser et al., 1988). 
Although the specific neurochemical mechanism re-
sponsible for behavioral sensitization remains elusive, 
available data suggest. that behavioral sensitization is 
accompamed by changes in presyn;iptic dopamine func-
tion (Kalivas and Stewart, 1991; Robinson and Becker, 
1986; Rowlett et al., 1991; Segal and Kuczenski; 1992; 
Zahniser et al., 1988) and/or changes in nondopamine 
pathways involved in feedback to the dopamine sys-
tems (Kalivas and Stewart, 1991; Karler et al., 1991). 
It is clear that behavioral sensitization requires the 
stimulation of dopamine receptors (Kuczenski and Le-
ith, 1981; Mattingly and Rowlett, 1989; Feris and Zah-
niser, 1989). Although behavioral sensitization consis-
tently has been shown to be unaccompanied by changes 
in dopamine receptor affinity or density (Mayfield et 
al., 1992; Robinson and Becker, 1986; Rowlett et al., 
1991), a role for the D1 subtype of dopamine receptor 
has been implicated for cocaine-, morphlne- and d-am-
. phetamine-i'nduced behavioral sensitization (Henry 
and White, 1991; Stewart and Vezina, 1989; Vezina and 
Stewart, 1989). Recent experiments from our labora-
tory also have indicated a role for D1 dopamine recep-
tors in the development of behavioral sensitization to 
apomorphine. For example, co-administration of the D1 
receptor antagonist SCH 23390 with repeated apomor-
phine prevents the development oflocomotor sensitiza-
tion to apomorphine (Mattingly et al., 1991). In con-
trast, co-administration of the D2 antagonist sulpiride 
does not prevent locomotor sensitization to apomor-
phine; despite sulpiride's ability to prevent the acute 
locomotor-activating effects of apomorphine (Mattingly 
et al., 1991). 
More recently, we have demonstrated that 10 daily 
injections of the D1-selective agonist SKF 38393 re-
sulted in locomotor sensitization to a subsequent chal-
lenge of apomorphine (Mattingly et al., 1993). Repeated 
treatment with quinpirole, a D21D3 agonist, also re-
sulted in locomotor sensitization to subsequent apo-
morphine challenge. However, this effect of repeated 
quinpirole was blocked by co-administration of SCH 
23390. This finding suggests that locomotor sensitiza-
tion observed after repeated quinpirole requires D1 re-
ceptor stimulation (Mattingly et al., 1993). Taken to-
gether, these results suggest a critical role of D1 
receptor stimuiation for locomotor sensitization to apo-
morphin.e. 
To date, the only neurochemical change consistently 
found after repeated apomorphine treatment is en-
hanced dopamine synthesis in the nigrostriatal and 
· mesolimbic terminal fields (Rowlett· et al., 1991; 
Vaughn et al., 1990). If this effect represents a mecha-
nism of behavioral sensitization to apomorphine, then 
the enhanced dopamine synthesis effect might be medi-
ated by D1 receptor stimulation. However, most avail-
able evidence indicates that D2 receptors, rather than 
D1 receptors, are.involved in the reguiation of dopamine 
synthesis (Brown et al., 1985; Wachtel .Pt al., 1989; 
White and Wang, 1984b; Wolf and Roth, 1990). To as-
sess this issue more fully, the present experiments ex-
amined the acute and rep.;ated effects of SKF 38393 
treatment on dopamine synthesis nieasured by accu-
mulation of 3,4-dihydroxyphenylalanine (DOPA) after 
DOPA decarboxylase inhibition. in addition, ·th~ 
present experiments assessed tissue levels of dopamine 
and 3,4-dihydroxyphenylacetic acid (DOPAC) following 
repeated SKF 38393 and apomorphlne treatments. 
Data from our laboratory indicated that, in contrast to 
DOPA levels, DOPAC levels are not elevated in rats 
treated with repeated apomorphlne (Rowlett et al., 
1991). However, Vaughn et al. (1990) did find elevated 
DOPAC arid DOPA levels in mouse striatum after 
treatment with repeated apomorphlne. Thus this study 
extended our previous work by asses~ing D1 effects on 
tissue DOPAC levels. Finally, the present experiments 
examined [3HJSCH 23390 binding to D1 receptors fol-
lowing repeated SKF 38393 and apomorphine treat-
ments. In all of the present experiments, we assessed 
dopamine function in the major terminal fields of the 
nigrostriatal and mesolimbic dopamine pathways: the 
striatum and nucleus accumbens-oifactory tubercle 
(NAOT), respectively. In addition, we included the ven-
tral mesencephalon (VM), whlch contains the cell bod-
ies of the nigrostriatal and mesolimbic dopamine sys-
tems, as changes in this area have been implicated as 
· crucial to the development of behavioral sensitization 
(Kalivas and Stewart, 1991). · 
MATERIALS AND METHODS 
Subjects 
Male Wistar albino rats (Harlan Industries, India-
napolis, IN), weighing 250-300 g, were used in each 
experiment. All rats were housed individually in a col-
ony room and maintained with food and water available 
continuously. Artificial lighting was provided from 
07.00 h to 19.00 h. All behavioral testing was conducted 
during the light phase of the cycle. 
Locomotor activity appatatus 
Activity measures were taken in two BRS/Lehigh 
Valley cylindrical activity drums (Model 145-03) that 
were 60 cm in diameter aµd 43 cm high. The interior of 
each drum was painted 
0
fllit'1>lack, and the floor was 
made of 4 cm diamond-shape. wire mesh. Each drum 
was· located in a separate sound-atten.;ated cubicle that 
was kept totally dark throughout testing. 
Two banks of three infrared photocells were mounted . 
on the outside of each drum. The photocells were -12 
cm apart and 2.5 cm above the drilm floor. The photo-
cell banks were connected to backpath eliminator di-
odes. Movement of the rat through the photocell beam 
sent a single pulse to the counters. SimiiJtaneous pulses 
(i.e., pulses spaced less than 0.05 s I apart), such as 
might_ occur when two beams are broken near theU. 
,. 
/ 
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intersection, were recorded as a sir..1:,le count by this 
method. Thus activity was defined as the cumulative 
number ofphotobeam interruptions per unit of time. 
Tissue dissections 
For dissections in the dopamine synthesis experi-
ments, rats were killed by rapid decapitation, and the 
brains were removed and placed on an ice-cold dissec-
tion plate. For the DOPA accumulation experiments, 
striatal and mesolimbic (nucleus accumbens and olfac-
tory tubercle combined, NAOT) samples were dissected 
from a coronal slice that extended from -0.2--3 mm 
anterior ·to bregma (Paxinos and Watson, 1986). The 
ventral mesencephalon (VM) was dissected similar to 
that diagrammed previously for the substantia nigra 
(Westerink and Korf, 1976), except that the AlO cell 
bodies were also included. Each sample was weighed· 
and placed in 0.1 M HC104 (100 mg/ml for the striatum 
and NAOT, 50 mg/ml for the VMJ and then frozen at 
-70°c 
Tissue dissections for the dopamine, DOPAC, and 
binding experiment were the same as those for the 
DOPA accumulation experiment, except that the stria-
tum included tissue removed posterior to the coronal 
sections used to obtain the NAOT. These tissue samples 
were placed on aluminum foil and immediately frozen 
on dry ice and then stored at -70°C. 
Assay for DOPA, DOPAC, and dopamine 
On the day of the dopamine and DO PAC assays, the 
brain regions were thawed on ice, weighed, and Soni: 
cated (Vibracell, setting 80) in 0.1 M HC104 (100 mg/ml 
for striatum and NAOT, 50 mg/ml for VMl. For the 
DOPA assays, the tissue samples were thawed and son-
icated. All tissue homogenates then were centrifuged at 
30,000 x g for 15 min (4'Cl. Supernatants (20 µ.[)were 
injected into a high-performance liquid chromatograph 
(HPLC I with an electrochemical detector (Bioanalytical 
Systems, LC-304T) and a temperature-controlled 
(25'C), 5-µ.m column IBioanalytical Systems, PN 6207). 
For DOPA determination, the mobile phase consisted of 
50 mM Na2HP04 , 124 mM citric acid, 0.1 mM EDTA, 
0.03% (w/vJ sodium octyl sulfate, and 10% (v/v) metha-
nol (pH 3.0). For DOPAC and dopamine assessment, 
.the mobile phase consisted of 50 mM Na2HP04 , 100 
mM citric acid, 0.1 mM EDTA, 0.025% (w/v) sodium 
octyl sulfate, and 20% (v/v) methanol (pH 3.2). The 
working electrode was maintained at+ 750 m V against 
the reference electrode (Ag/AgCl, Bioanalytical Sys-
tems). Standards of DOPA, DOPAC, and dopamine 
were assayed daily. 
Assay for D1 receptors 
The tissue sample (n = 4 striatum, n = 6 for both 
NAOT and VM) were assessed for D1 dopamine recep-
. tor binding using the radioligand [3H]SCH 23390. Sat-
uration experiments were performed on striatal tissue 
samples, whereas single concentration assays Were per-
formed on NAOT and VM samples. For the binding 
assays, the tissue samples were thawed on ice and then 
homogenized (Brinkmann Polytron, setting 5 for 10 s) 
i!' 1 ml ice-cold 50 mM Tris buffer (pH 7.4 at 37°CJ. The 
volume of the resulting tissue suspension was brought 
to approximately 10 ml and centrifuged at 40,000 x g 
for 10 min (4°C). The supernatant was discarded and 
the pellet homogenized and centrifuged as described 
above. After this final centrifugation, the pellet was 
re-suspended and homogenized in 50 mM Tris buffer 
containing 120 mM NaCl and 0.5 mM EDTA (pH 7.4 at 
37°C). The final tissue concentrations were as follows: 
Striatum, 2 mg/ml; NAOT and VM, 2.5 mg/ml. 
The tissue suspensions were added to the incubation 
medium (1 ml final volume) which contained 50 mM 
Tris with 120 mM NaCl and 0.5 mMEDTA (pH 7.4 at 
37°CJ, [3H]SCH 23390 (0.1-4.0 nM over six concentra-
tions for saturation experiments, 1.0 nM for single con-
centration experiments), in the presence and absence of 
1 µ.M ( + )-butaclamol. In order to reach equilibrium, the 
incubation time was 30 min at 37°C. The equilibrium 
reaction was terminated by vacuum filtration (What-
man GF/B glass fiber filters). The filters were pre-
soaked for 30 min in 0.1 % (v/v) polyethylenimine and 
during the filtration were washed of unbound [3HJSCH 
23390 with 50 mM Tris buffer. After filtration, the fil-
ters were placed in glass vials with 8 ml scintillation 
fluid (Budget-Solve, Research Biochemicals) and radio, 
activity was measured using liquid scintillation spec-
trometry (Packard 3380 with -25% counting effi-
ciency). Specific binding was defined as the difference 
in bound radioactivity obtained in the presence and 
absence of 1 µ.M ( + l-butaclamol. · 
Drugs and radioligand 
Apomorphine hydrochloride (Sigma) was dissolved 
daily in 0.001 N HCl and injected in a volume of 1.0 
ml/kg. SKF 38393 I 1-phenyl-2,3,4,5-tetrahydro-!lH0-
3-benzazepine-7,8-diol hydrochloride, Research Bio-
chemicals) was dissolved daily in 0.001 N HCl in a 
volume of 1.5 ml/kg. NSD-1015 (M-hydroxybenzylhy-
drazine dihydrochloride, Sigma) was dissolved daily in 
isotonic saline. DOPA, DOPAC, and dopamine stan-
dards were purchased from Sigma and were mixed in 
0.1 M HCI04 . ( + )-Butaclamol hydrochloride (Research 
Biochemicals) was dissolved in 100% (v/v) ethanol at a 
concentration of 10 µ.M and diluted to 1 µ.M in 50% 
ethanol. [3HJSCH 23390 (Amersham, 73 Ci/mmol) was 
diluted in the incubation Tris buffer. 
Procedures 
Dopamine synthesis experiments 
In order to determine the effects of acute SKF 38393 
on· dopamine synthesis, rats were injected SC with ve-
hicle or 8 mg/kg SKF 38393 (n = 12 per group). Fifteen 
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min later, all rats received NSD-1015 (100 m"/kg, IP) 
and were sacrificed 30 min later by rapid decapitation 
for the dissections 
In order to determine the effects ofrepeated apomor-
phine and SKF 38393 treatments on dopamine synthe-
sis, separate groups of rats (n = ~11 per group) were 
injected with vehicle, apomorphine (5 mg/kg, SC) or 
SKF 38393 (8 or 16 mg/kg, SC) and returned to their 
home.cage. Fifteen min later, each rat was placed into 
an activity drum and locomotor activity was measured 
for 20 min, after which the rat was returned to its home 
cage. This procedure was repeated daily for 10 consecu-
tive days. On day 11, the rats received NSD-1015 (100 
mg/kg, IP) and were sacrificed 30 min later by rapid 
decapitation for the dissections. 
DOPAC, dopamine, and D 1 l;>inding experiment 
Three groups ofrats (n = 12 per group) were admin-
istered vehicle, apomorphiiie (5· mg/kg, SC) or SKF 
3B393 (16 mg/kg, SC) and locomotor activity was as-
sessed daily for 10 days as described for the dopamine 
synthesis experiment. On day 11, the rats were sacri-
ficed by rapid decapitation for the dissections. One-half 
of each group was used for the DOPAC and dopamine 
assays, the other half was used for [3HJSCH 23390 
binding experiments. 
Data analysis 
For the acute. ·DOPA accumulation experiment, 
DOPA levels were analyzed using independent t-tests 
(two-tailed). For the chronic experiments, locomotor ac-
tivity, DOPA accumulation, dopamine, and DOPAC 
data were each analyzed with mixed factorial analysis 
of variance <ANOVA) with drug as the between-sub-
jects factor and day or brain region as the within-sub-
jects factor. In some cases, the mixed factorial ANOVAs 
were followed by one-way ANOVAs for the various 
brain regions. In ANOVAs involving repeated mea-
sures, violations of homogeneity of variance were exam-
i~ed using the Huyn-Feldt epsilon. Degrees of freedom 
w"ere corrected if the epsilon value was <0. 75. Multiple 
comparisons \vere made using the Dunnett's test com-
paring the drug groups to the vehicle control (a = 0.05). 
The results of the repeated drug-dopamine synthesis 
study were compared to the dopamine synthesis results 
ofour previous study (Rowlett et al., 1991) using meta-
analytic statistical procedures (Rosenthal, 1984). Effect 
size (r) was computed from F-ratios of the comparisons 
of control to repeated apomorphine treatment and a 
Z-score was computed according to Rosenthal (1984). 
The Z-score for the comparison of r values for the two 
studies was considered significant at P <;; 0.05. 
For the saturation studies conducted on the striatal 
tissue homogenates, K0 and Bmax values were obtained 
from Scatchard analyses using the EBDA software pro-
gram (Elsevier Biosoft, Cambridge, UK). When a single 
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Fig. 1. Locomotor activity following 10 daily injections of vehicle 
(VEH), 5 mg/kg apam_orphine (APO), B mg/kg SKF 38393 [SKF(8)] or 
16 mg/kg SKF 38393_ [SKF(!6)]. Locomotor activity was measured as 
total counts (photobeam couiits cumulated over.20 minutes) assessed 
15 minutes after injection of drug or .vehicle each day. Each drug group 
consisted of9-11 rats. .- ' 
' 
concentration of radio!igand was used, the Bmax value 
was estimated using the equation (Boyson et al., 1986): 
B(L +Kol 
B' = 
m~ L 
In the equation, B is the amount of [3H]SCH 23390 
specifically bound at radioligand concentration L. The 
K0 values were obtained from pilot experiments per· 
formed with NAOT and VM samples of untreated rats. 
The K0 , Bmax and B' max data were analyzed for treat-
ment effects using separate one-way ANOVAs. Posthoc 
comparisons were made using Dunnett's test~ \vith 
a= 0.05. 
RESULTS 
Locomotor activity 
Locomotor activity data from the animals used in the 
dopamine synthesis experiment are shown in Figure 1. 
The locomotor activity data from the animals used in 
the DOPAC and receptor binding experiment repli-
cated these data and therefore are not shown. A mixed 
factorial ANOVA revealed a sigrtlficant main effect of 
drug, F(3,333) = 129.2, P < 0.001, and day, F(9,333) = 
3.67, P < 0.001, as well as a significant drug x day in-
teraction, F(27,333) = 31.75, P < 0.001 (epsilon= 
0.79). Apomorphine produced no effect on activity on 
day 1 (Dunnett's test, P > 0.05); however, activity 
counts increased progressively aver , the remaining 
days. In contrast, SKF 38393 tended t~ decrease activ-
ity in a dose-related manner. For example, the 8 mg/kg 
dose produced sigrtlficant decreases in activity on days 
6 and 7 only, whereas the 16 mg/kg dose produced sig-
mficant decreases on 7 of the 10 days (Dunnett's test, 
P < 0.05). In general, the effects of both doses of SKF 
/ 
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TABLE/. 3,4-dihydroxyphenylalanine (DOPAJ accumulation in rat 
striatum. nucleus accumbens-olfactory tubercle (NAOTJ, and ventral 
mt·i=-ncephalan (VM) following acute SKF 38393 (8 mg'kgJ 1 
Vehicle 
SKF 38393 
DOPA Cmean µ.gig± SE1Il 
n Striatum NAOT VM 
12 
12 
1.99 :!:: 0.11 
1.89 :!:: 0.14 
1.88 :!:: 0.08 
1.77 :!:: 0.13 
1.02 :!:: 0.08 
0.91 :!: 0.08 
1Each region was analyzed separately using independent t-tests (two-tailed), which 
revealed no significant differences between vehicle and SKF 38393 groups. 
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Fig. 2. Dopamine synthesis. measured as 3,4-dihydroxyphenylala-
nine ( DOPAI accumulation after DOPA decarboxylase inhibition \vith 
NSD-1015. following 10 daily injections of vehicle !VEH), 5 mg/kg 
apomorphine !APO), 8 mg/kg SKF 38393 [SKF(8Jl or 16 mg/kg SKF 
38393 [SKFl161I. The rats In= 9-11 per group> were sacrificed 24 
hours after the last ihjection of drug. *Note that P < 0.05 compared to 
VEH. groups using Dunnett's tests. 
38393 on locomotor activity did not change across days 
(see Fig. 1). 
Dopamine synthesis 
DOPA accumulation following acute SKF 38393 
treatment is presented in Table I. Independent t-tests 
revealed no significant effects of drug treatment in any 
brain region: Striatum, t(22) = 0.57; NAOT, t(22) = 
0.70; VM, t(22) = 1.05; P > 0.05 in each case. 
DOPA accumulation following repeated apomor-
phin., and SKF 38393 treatments is shown in Figure 2. 
Mixed factorial ANOVA revealed a significant main ef-
fect of drug, F(3,36) = 2.96, P < 0.05, and region, 
Fl.:2,72) = 155.77, P < 0.001 (epsilon= 0.94). The in-
teraction of drug and region approached significance, 
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Fig. 3. Ventral mesencephalon levels of 3,-4-dihydroxyphenylacetic 
acid (DOPAC> and dopamine in rats (n = 5-6.per group) treated with 
10 daily injections of vehicle (VEH), 5 mg/kg apomorphine <APO) or 16 
mglkg SKF 38393 [SKF(!6)]. *Note that P < 0.05 compared to VEH 
group, Dunnett's test. 
F(3, 72) = 4.36, P = 0.07. Dunnett's tests revealed that 
DOPA levels were significantly enhanced by repeated 
apomorphine in the striatum (P < 0.05). DOPA levels 
were significantly decreased by the ·3 mg/kg. dose of 
SKF 38393 in the striatum and by the 16 ing/kg dose in 
theNAOT. 
For the comparison of the effects of vehicle and apo-
morphine treatments on DOPA levels, the effect sizes 
for the striatum and NAOT were as follows: Striatum. 
r = 0.49; NAOT, r = 0.23. These effect sizes were simi-
lar to that of our previous study (Rowlett et al., 1991 I: 
Striatum, r = 0.43 [for F(l,60) = 13. 72]; NAOT. 
r = 0.27 [for F<l,601 = 4.34]. For both striatum and 
NAOT, the effect sizes between the two experiments 
were not significantly different: Striatum, Z = 0.40, 
P = 0.69; NAOT, Z = 0.34, P = 0. 73. Thus the signifi-
cant increase in DOPA accumulation previously ob-
served in the NAOT (Rowlett et al., 1991) is probably a 
relatively small effect and was significant in the previ-
ous study due to the large sample size (n = 16 per 
group). 
DOPAC and dopamine levels 
Figure 3 presents DOPAC and dopamine levels for 
the VM. DOPAC and dopamine levels for the remaining 
two brain regions are presented in Table II. Mixed fac-
torial ANOVA revealed only a significant effect of re-
gion for DOPAC, F(2,28) = 338.6, P < 0.001 (epsi-
lon= 0.80). A separate one-way ANOVA performed on 
DOPAC data from the VM revealed a significant effect 
of drug, F(2,14) = 8.13, P < 0.05. A subsequent Dun-
-\ •. 
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TABLE II. 3,4-Dihydro:Cjtphenylacetic acid (DOPACJ and dopamine 
values in rot striatum and nucleus accumbens-olfaclory tubercle 
(NAOTJ following repeated treatments with apomorphirn! (5 mglkgJ 
or SKF 38393 (16 mg/kg) 1 
Striatum NAOT 
DOPAC Dopamine DOPAC Dopamine 
Vehicle 2.7 ± 0.2 7.9 ± 0.5 2.1 ± 0.2 4.0 ± 0.5 
Apomorphine 2.8 ± 0.1 7.3 ~ 0.3 2.1 ± 0.2 4.1 ± 0.4 
SKF 38393 2.7 ± 0.2 7.1 ± 0.5 1.9 ::!:: 0.1 4.0 ± 0.3 
1Va1ues for DOPAC and dopamine are in µgig tissue. No signifJ£ant treatment effects 
were observed. The sample sizes were n = 6 for both stria tum and NAOT. 
TABLE Ill. £3HJSCH 23390 bindiizg to D 1 dopamine receptors in rat 
striatum, nucleus accumbens-olfactory tubercle (NAOT), and ventral 
mesencephalon (VM) following repeated treatment with vehicle, 
apomorphine (5 mg/kg) or SKF 38393 (16 mg/kg) 1 
Striatu.m · NAOT VM 
Ko B_ , B'mrui: B'-
Vehicle 580.1 ± 38.5 56.5 ~ 5.8 33.9 ~ 2.0 24.0 ± 5.5 
Apomorphine 525.6 ± 26.8 59.4 ± 4.9 31.8 ± 2,0 28.2 ± 3.1 
SKF38393 520.9 ± 43.4 56.5 :!: 5.8 36.4 :t L6 24.B ± 6.9 
1Valuea for Kn are inpM, values forBmu and B'mu are in finoVmg tissue. 'llie Ko and 
B,,..,. valuea were derived from Scitchard analyses of saturation experiments. The B' mu 
values were derived using the equation (Boyson et al., 1986) B'"""' ,,, BCL + KnYLi in 
which B is the specific binding at radioligand concentration L. Kn was derived from pilot 
saturation uperiments in the NAOT and VM. No significant treatment effects were 
observed. 'The Ko and Bmu values were obtained from four independent experimentS 
per group, whereas the sample sizes for the NAOT and VM were n = S-..0. 
(Mattingly et al., 1993). Taken together, these results 
indicate that D1 receptors may be involved in the devel-
opment of locomotor sensitization, whereas D2 stimula-
tion may be necessary for the expr~ssion ·of locomotor 
sensitization. Other behaviors su~h as acute SKF 
38393-induced stereotypic motor: responses (e.g., 
tongue protrusions) or rotational behavior after unilat-
eral .6-hydroxydopamine lesion havk been reported to 
sensitize with repeated injections of SKF 38393 alon'e 
I . 
(Braun and Chase, 1988; Matsuda et al., 1992; 
Neisewander et al., 1991; White et hl., 1990), suggest-
ing that some forms ofD1 mediated ~ensitiiation do not 
require D2 stimulation for the expre~sion of the behav-
ior. I ' 
It is evident from the present res1'.lts·that repeated 
D1 stimulation by SKF 38393, unlike-repeated D/D2 
stimuJation by apomorphlne, dries in0t:;-result in en-
hanced dopamine synthesis,. iji; fa&;;repeated SKF 
38393 t,reatment resulted in small d~_Cl"eases in dopajll-
ine synthesis in the stria tum and NA()T.:This finding-i~ 
somewhat surprising since:acute SKF 38393 had no 
effect on DOPA'accumulation' Inde~d;.Wachtel et al.· 
(1989) also demonstrated that SKF 38393 had no effect · 
on DOPA accumulation ove~ a wide ri.nge of doses after 
impulse flow inliibition by gamma-b.;tyrolactone. Some 
evidence has suggested that D1 stimdiation may modu-nett's test demonstrated that repeated apomorphlne , 
treatment resulted in enhanced DOPAC levels in the late the electrophysiological characteristics of rtigro-
\7¥ (P < 0.05, see Fig. 3), whereas repeated SKF 38393. striatal dopamine neurons. For example, Diana et al. 
(1989, 1991) have shown that SKF 38393 reduces the had no sigrtificant effect. • · 
excitability of nigrostriatal neurons; measured as an , Analyses of dopamine levels for the three brain re-
. 1 d · ·r· t d d x · . · increase in threshold stimulating current ·required to gtons revea e no s1gm 1can rug or rug region m- 1 
.elicit antidromic stimulation in th.e terminal field. teraction. The main effect of region was significant, 
F(2,26) = 273.17, p < 0.001 (epsilon= o.90). Therefore, dopamine neuron impulse flow may be al-
tered after repeated SKF 38393 treatment. In the 
D1 dopamine receptors present study, DOPA accumulation was measured 
Table III presents the mean Ko, Bm=• and B 'm= val- without inhibition of impulse flow; thus the small de-' 
ues for the different brain regions. [3HJSCH 23390 sat- crease in DOPA accumulation found after repeated 
uration experiments in the striatum revealed linear SKF 38393 may be the result of decreased impulse flow 
functions, consistent with a homogeneous population of of dopamine neurons in the striatum!and NAOT. How-
binding sites. No significant effects of drug treatment ever, much evidence indicates that D; stimulation does 
were observed for any of the brain regions. not alter nigrostriatal or mesolimbic 'dopamine cell ac-
DISCUSSION 
Consistent with previous work (Castro et al., 1985; 
Mattingly and Gotsick, 1989; Mattingly and Rowlett, 
1989; Mattingly et al., 1988a,b, 1991, 1993; Rowlett et 
al., 1991), repeated stimulation of D1 and D2 receptors 
with apomorphine resulted in locomotor sensitization. 
Also consistent with a study from our laboratory (Mat-
tingly et al., 1993), repeated stimulation ofD1 receptors 
with SKF 38393 dose-dependently decreased activity 
and this decrease did not change across days. Thus, D1 
stimulation alone does not appear to result in locomotor 
sensitization. However, previous work has shown that 
rats pretreated with repeated SKF 38393, at doses used 
in the present study, demonstrate locomotor sensitiza-
tion when subsequently challenged with apomorphlne 
tivity (Carlson et al., 1987; Wachtel et al., 1989). Since 
the effect of repeated SKF 38393 treatment was some-
what small in magnitude, further investigation of the 
nature and reliability of this effect is warranted. 
Regardless of the mech.anism ofde~reased DOPA ac-
cumulation after· repeated SKF 38393 treatment, it 
seems clear that the enhanced dopamine synthesis ef-
fect observed after repeated apomorphlne treatment is 
not mediated by D1 receptors. Sine~ behavioral evi-
dence strongly indicates a crucial role' for-the D1 recep-
tor in the development of locomoto~ sensitization to 
apomorphine (Mattingly et al., 1991,11993), enhanced 
dopamine synthesis may reflect a consequence of re-
peated apomorphlne treatment that is~not critical to the 
development of apomorphine-induced behavioral sensi-
tization. ! 
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Because much evidence indicates modulation of 
dopamine synthesis by D2 autoreceptors (Brown et al., 
1985; Wachtel et ·al., 1989; Wolf and Roth, 1990), the 
enhanced dopamine synthesis effect produced by re-
peated apomorphine may reflect a reduction in D2 au-
toreceptor sensitivity, In support of this hypothesis, 
acute apomorphine-induced inhibition of striatal and 
nigral firing rate has been shown to be significantly 
attenuated by repeated apomorphine treatment (Jezi-
orski and White, 1989; Rebec and Lee, 1982). Evidence 
for autoreceptor subsensitivity .also has been found af-
ter repeated amphetamine (White and Wang, 1984a) 
and repeated cocaine treatment (Henry et al., 1989). 
With both repeated amphetamine and cocaine treat-
ment, basal firing rates and the number of spontane-
ously active ventral tegmental dopamine neurons are 
enhanced (Henry et al., 1989; White and Wang, 1984a). 
Thus the increase in basal dopamine synthesis after 
repeated apomorphine treatment may reflect an in-
crease in basal dopamine neuron activity. 
Some findings are difficult to reconcile with the hy-
pothesis that repeated apomorphine treatment induces 
autoreceptor subsensitivity. For example, the ability of 
low doses of apomorphine to attenuate amphetamine-
induced sensitization does not change with repeated 
exposures (Riffee et al., 1987), although this finding 
may reflect the existence of spare D2 autoreceptors 
masking down-regulation (Jeziorski and White, 1989). 
Neurochemical effects believed to reflect autoreceptor 
stimulation, su.ch as acute apomorphirie-induced de-
creases in DOPAC levels and DOPA accumulation, are 
not altered by repeated apomorphine treatment (Rod-
riguez and Castro, 1991; Rowlett et al., 1991; Vaughn et 
al., 1990). Finally, D2 antagonist treatment does not 
prevent behavioral sensitization to amphetamine IVez-
ina and Stewart, 1989) or apomorphine (Mattingly' et 
al., 1991 l, although D2 antagonist treatment would re-
sult in increased dopamine neuron firing rate similar to 
a loss of autoreceptor sensitivity (White and Wang, 
. 1984bl. Regardless of the mechanism .responsible for 
. increased impulse flo\v of dopamine neurons after re-
peated dopamine agonist treatment, our neurochemical 
results generally parallel electrophysiological data that 
indicate that basal dopamine neuronal activity is en-
hanced after repeated indirect dopamine agonist treat-
ment. 
Another finding of these experiments is the elevated 
tissue levels of DO PAC in the VM after repeated apo-
morphine treatment. This finding is generally consis-
tent with recent research that implicates the VM cell-
body regions ofmesolimbic dopamine neurons (ventral 
tegmental area) in the development of sensitization to 
cocaine and amphetamine (Kalivas and Stewart, 1991). 
Interestingly, the increase in DOPAC occurred without 
an increase in dopilnine synthesis. Conversely, en-
hanced DOPA accumulation in the striatum was not 
accompanied by increases in DOPAC, a finding that 
replicates our previous study (Rowlett et al., 1991). 
Taken together, these findings suggest that changes in 
the formation of DOPAC and synthesis of dopamine 
induced by repeated apomorphine occur independently. 
DOPAC may be derived, at least in part, from newly 
synthesized dopamine not yet stored in vesicles or re-
leased into the synapse (Zetterstriim et al., 1988). Since 
striatal DOPAC levels were not altered by repeated 
apomorphine while striatal dopamine synthesis was 
enhanced, potential changes in dopamine function in 
the terminal field may not involve newly synthesized 
dopamine. In the VM, enhanced DOPAC levels were not 
accompanied by enhanced dopamine synthesis. There-
fore, this enhanced DOPAC effect probably does not 
reflect changes in newly-synthesized dopamine in the 
cell body region. 
Besides direct changes in dopamine metabolism, the 
enhanced levels of DOPAC in the VM may be due to 
several mechanisms. First, enhanced DOPAC levels 
may reflect' enhanced somatodendritic dopamine re-
lease due to decreased impulse-regulating autoreceptor 
sensitivity (Henry et ;il., 1989; Jeziorski and White, 
1989; Rebec and Lee, 1982; White and Wang, 1984a; 
Wolf and Roth, 1990). Second, repeated apomorphine 
may induce an increase in dopamine transport into VM 
cells, res\tlting in decreased stimulation of autorecep-
tors by dopamine and increased availability of dopam-
ine for metabolism into DOPAC. A third mechanism 
may be decreased inhibition of dopamine cells by othet 
neurotransmitters such as .gamma-aminobutyric acid 
(GABA). Indeed, it has b_een suggested that nondopam-
ine feedback onto mesencephalic dopamine neurons 
may be mediated by D1 receptors and is critical for the 
development of sensitization to psychostimulants (Ka-
livas and Stewart, 1991). Although this third mecha-
nism may be most consistent with the behavioral re-
sults implicating a critical role for D1 receptors in the 
development of sensitization (Mattingly et al., 1991. 
1992), enhanced DOPAC levels were not found after 
repeated SKF 38393 treatment. Thus these data indi-
cate that the enhanced DOPAC effect, similar to en-
hanced dopamine synthesis, is not mediated by re-
peated D1 stimulation. 
Reconciliation of the neurochemical findings of the 
present study and the findings from our behavioral 
studies, which suggest D1 involvement in behavioral 
sensitization to apomorphine may lie in an hypothesis 
advanced by Henry et. al. (1989). Specifically, these in-
vestigators suggested that repeated indirect dopamine 
agonist treatment results in impulse-regulating au-
toreceptor subsensitivity followed by terminal field D1 
receptor supersensitivity. Indeed, electrophysiological 
data indicates that D1 mediated postsynaptic responses 
are enhanced after repeated treatment with amphet-
amine (Higashi et al., 1989), cocaine (Henry and White, 
1991), and SKF 38393 (Kelland et al., 1991; White et 
al., 1990). Thus repeated apomorphine treatment may 
' 
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result in impulse-regulating autoreceptor subsensitiv-
ity, reflected as an increase in terminal field dopamine 
synthesis and enhanced DOPAC formation in the cell 
bodies. This may be followed by supersensitive D1 re-
ceptor function, reflected in the ability of D, antago-
nism to block the development of apomorphine sensiti-
zation. 
Similar to D2 receptor binding, repeated apomor-
phine. treatment did not alter [3H]SCH 23390 binding 
to D1 sites in the striatum, NAOT or VM. Thus, D1 
mediation of locomotor sensitization to apomorphine 
does not appear to involve alterations in D1 receptor 
density. It is possible, however, that changes in D1 re-
ceptor agonist-sensitive conformational states or D1-
mediated signal transduction may be responsible for 
the development of behavioral sensitization to apomor-
phine (cf., Henry and White, 1991). 
Repeated SKF 38393 treatment also did not result in 
changes in D1 binding. This finding is consistent with 
.recent experiments that demonstrated no effect of re-
peated SKF 38393 treatment on D1 sites (Matsuda et 
al., 1992; Neisewander et al., 1991). However, a recent 
study found an up-regulation ofD1 sites in rat striatum, 
nucleus accumbens, and substantia nigra following 
daily treatment of 10 mg/kg SKF 38393 (Subramama-
niam et al., 1992). The reason for this discrepancy is not 
clear, and further research on methodological factors 
(e.g., dose, length, and route of administration) is war-
ranted. 
In conclusion, the present results suggest that en-
hanced dopamine synthesis observed after repeated 
apomorphine treatment is not mediated by repeated D1 
stimulation. Since behavioral evidence clearly indi-
cates a necessary role for D1 receptor stimulation in the 
development of locomotor sensitization to apomor-
phine, enhanced dopamine synthesis in the terminal 
fields likely is not the primary neurochemical change 
responsible for locomotor sensitization. The finding 
that DOPAC levels were enhanced in the VM is consis-
tent with previous work with psychostimulants that 
i.mplicates the cell body regions of the nigrostriatal and 
mesolimbic dopamine pathways in the development of 
behavioral sensitization. Both the enhanced dopamine 
synthesis effect in the terminal fields and the enhanced 
DOPAC effect in the cell bodies after repeated apomor-
phine treatment may reflect increased basal impulse 
flow in dopamine cells. Finally, D1 dopamine receptor 
density and affinity were not affected by repeated 
dopamine receptor stimulation, indicating that simple 
changes in dopamine receptor number cannot account 
·for behavioral sensitization to apomorphine. 
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